Differential analysis of CD4(+) Th memory clones with identical T-cell receptor (TCR)-αβ rearrangement (non-transgenic), but distinct lymphokine phenotype, reveals diverse and novel gene expression

This study describes a subtractive hybridization analysis to identify differences in gene expression between sibling Th memory clones, elicited by virus infection and expressing identical T-cell receptor (TCR)-αβ rearrangements but distinct lymphokine phenotype: clone Bpp9 secretes interleukin (IL)-4, IL-5 and IL-10; clone Bpp19 secretes interferon (IFN)-γ, low levels of IL-4, and IL-5 on TCR ligation. cDNA sequencing of difference products (DP) identified both novel and known regulatory (DNA: RNA-binding) or signalling proteins (kinases: phosphatases). Of the 10 novel genes identified, three were putative membrane proteins, one a predicted nuclear protein containing a PEST sequence motif, one a predicted transporter fragment and one contained a zinc-finger motif. One of the membrane proteins was found only in RNA from the activated IFN-γ-producing clone, i.e. not in other tissues. In addition, a high frequency of granzyme A, B, C and G transcripts (for clone Bpp9) or transcripts for CD94 and NKG2A (for clone Bpp19) were expressed differentially, together with transcripts that mapped to, so far, unassigned regions of the mouse genome that may be further novel genes. The transcriptional profiles presented here may therefore include candidate regulators of Th diversity and effector function

Adjuvant effect of Ubenimex on a DNA vaccine for HIV-1

Enhancement of DNA vaccine immunogenicity is a current topic of high priority in the field of applied immunology, especially as a means of controlling HIV infection. The adjuvant effect of Ubenimex (UBX), an anti-cancer immunomodulator, on a DNA AIDS vaccine which we developed was examined in a murine model. UBX was formulated into a preparation containing DNA plasmids encoding env and rev genes of HIV-1 strain IIIB, and was inoculated intramuscularly into BALB/c mice. The sera obtained with this mixture had 23–25 times higher specific IgG titres than those obtained without the use of the adjuvant. UBX also elicited both a stronger HIV-1-specific DTH reaction, as measured by the footpad swelling test, and stronger cytotoxic T lymphocyte activity, as assayed by the 51Cr-release method, compared with responses using DNA alone. The cytokine secretion profile of restimulated immune lymphoid cells showed that UBX raised IL-2 and interferon-gamma levels and decreased IL-4 production. HIV-1-specific immunoglobulin subtype analysis demonstrated that UBX stimulated IgG2a production but suppressed synthesis of IgG1 and IgE. These results indicate that activation of the T-helper type 1 subset was induced by UBX, suggesting a mechanism of immunomodulation mediated by this agent. We conclude that UBX acts as an immunologic adjuvant for DNA vaccination against HIV-1. UBX may be a suitable adjuvant for clinical use because of its lack of antigenicity and low toxicity